Background
==========

Age-related macular degeneration (AMD) is the leading cause of blindness among people aged 55 years and older in the U.S and other Western countries \[[@B1]-[@B3]\]. Late stage AMD includes two morphological sub-types: neovascular AMD and geographic atrophy \[[@B4],[@B5]\]. Population studies indicate that neovascular AMD accounts for two thirds of late AMD cases, and 90% of blindness from AMD \[[@B6]\]. Left untreated, neovascular AMD results in severe visual impairment with an average loss of around 4 lines of visual acuity within 2 years of disease onset \[[@B7]\]. Patients with geographic atrophy also develop visual loss although this tends to be more gradual.

With the introduction of new and effective treatments for neovascular AMD, there is a strong rationale for early identification of persons at highest risk of progression to the late stages as timely treatment given at the onset of neovascular AMD will lead to better visual outcomes \[[@B8]-[@B11]\]. In this regard, a number of major risk factors for AMD have been identified, including genetic (e.g., complement factor H polymorphisms), demographic (e.g., ethnicity), nutritional (e.g., antioxidant vitamins, dietary fats or fish), lifestyle (e.g., smoking), medical (e.g., cardiovascular risk factors), environmental (e.g., sun exposure), and ocular factors \[[@B12]-[@B16]\]. However, the evidence and strength of association remain variable in the literature. Furthermore, a number of these risk factors (e.g., diet and genetic factors) are not easily measured in routine clinical practice \[[@B17]-[@B21]\]. While ocular clinical signs such as drusen and pigmentary irregularities are important markers for progression to late AMD \[[@B22]\], the skills required for an appropriate retinal evaluation to be performed followed by the interpretation of the severity of the signs to make a meaningful judgement of risk observed are limited to those with retinal specialist knowledge. The impending explosion in immunomodulatory pharmacotherapies which are in currently in early phase clinical trials constitute another important reason for non-specialist clinicians and general ophthalmologists to be able to refer persons at very high risk of development of late AMD. Therefore it was our view that more precise estimates of risk for factors that could be assessed through routine history taking would be of value for appropriate counselling and referral.

Methods
=======

Selection of Risk factors
-------------------------

We performed a systematic review and meta-analysis of a selection of risk factors for late AMD (neovascular AMD and geographic atrophy). Initially, we scrutinized in detail the literature on late AMD to identify all possible risk factors. The initial search yielded 73 possible risk factors (Table [1](#T1){ref-type="table"}). Following review by an expert panel (UC, AF, PM, TYW), 16 factors that were considered to be readily measured in nonspecialist settings were selected for the full systematic review. We did not address ocular or genetic risk factors as these require either specialist skills to conduct the retinal examination or access to laboratory resources and genetic expertise. We also excluded nutrition as an estimation of the nutrition status through dietary questionnaires is also a specialised field \[[@B23]\].

###### 

Potential 73 Risk Factors for Late Age-related macular degeneration, Identified in the Initial Review

  -----------------------------------------------------------------------------------------------------------------------------------
  • **Ocular factors (n = 15)**
   • Nuclear opacity
   • Cortical opacity
   • Pterygium
   • Lens opacity
   • Horizontal cup-to-disc ratio
   • Fellow eye
   • *Iris color*\*^†^
   • Eye disease\*
   • *Cataract/Cataract surgery*\*^†^
   • Arcus cornea
   • Arterioar-to-venular ratio
   • Frekling
   • Spherical equivalents
   • Eye glasses for distance vision
   • *Family history of AMD*^†^
  • **Cardiovascular factors (n = 7)**
   • Atherosclerosis
   • *History of CVD and cerebrovascular disease*\*^†^
   • *Serum Total Cholesterol level*^*†*^*and Serum HDL Cholesterol level*^*†*^
   • *Hypertension*\*^†^
   • Plasma antioxidants
  • **Other medical conditions or marker (n = 8)**
   • Biochemical variables\* including serum albumin, *C-Reactive Protein*,\*^†^*plasma fibrinogen*,^†^and *serum triglyceride*^†^)
   • Bone mineral density
   • *Diabetes*\*^†^
   • Arthritis
   • Menopause
  • **Diet (n = 11)**
   • Dietary intake
   • Fat\*
   • Animal fat\*
   • Vegetable fat\*
   • Linoleic acid
   • ∞-3 fatty acids EPA/DHA
   • Antioxidants\*
   • Saturated fat
   • Monounsaturated fat
   • Polyunsaturated fat
   • Trans-unsaturated fat
  • **Medications (n = 9)**
   • Birth control use
   • Diuretics use
   • Antacid use
   • Antihypertensive medication use
   • Anti-inflammatory drug use
   • Hydrochlorothiazide use
   • Hormone replacement therapy
   • Hormones (women)
   • Hypnotics/sedative
  • **Life style (n = 3)**
   • *Smoking*\*^†^
   • Alcohol consumption
   • Physical activity level
  • **Light and other exposures (n = 3)**
   • Place of birth
   • Solar radiation/outdoor exposure\*
   • Chemical exposure
  • **Genetics (n = 9)**
   • fibulin 5
   • CST3
   • CX3CR
   • TLR4
   • VEGF
   • LRP6
   • MMP9
   • HLA family of genes
   • CFH
  • **Demographics (n = 8)**
   • *Gender*\*^†^
   • *Age*\*^†^
   • *Race/ethnicity*\*^†^
   • Education\*
   • *Weight/Body mass index*\*^†^
   • Waist circumference
   • Height
   • Marital status
  -----------------------------------------------------------------------------------------------------------------------------------

Data Sources
------------

Searches were conducted in Medline and Cochrane databases using these terms: macular degeneration OR age-related macular degeneration OR age-related maculopathy AND gender OR age OR race OR ethnicity OR iris colour OR diabetes OR cardiovascular OR cerebrovascular OR hypertension OR smoking OR cataract surgery OR family history OR body mass index OR cholesterol OR fibrinogen OR C-reactive protein OR triglyceride.

Studies and Participants
------------------------

Prospective cohort, case-control, or cross-sectional studies, were included if they incorporated an estimate of association \[odds ratio (OR) or relative risk (RR)\] between late AMD and at least one of the 16 risk factors. Non-English language articles were not included because, after a preliminary assessment, we did not identify any that fitted our inclusion criteria. Abstracts and unpublished studies were also not included.

For articles that passed initial screen, additional criteria were applied for inclusion in the meta-analysis: 1) estimates for association with neovascular AMD and geographic atrophy were excluded when concomitantly presented as late AMD to avoid double counting; 2) for three epidemiological studies that examined the risk of late AMD (i.e., Beaver Dam \[[@B24]-[@B26]\], Blue Mountains \[[@B24]-[@B26]\], and Rotterdam \[[@B25],[@B26]\]) both the original estimates and pooled estimates of the three studies exist. Therefore, to avoid double counting of these studies, only the pooled estimate was retained. We did not include studies that reported only the unadjusted results (i.e., crude ORs). All studies included adjusted for age; when studies reported more than one adjusted estimate, the multivariate adjusted estimate was selected (i.e., if a study reported either age adjusted or age, gender and smoking adjusted results, the latter was chosen).

Outcome Measures
----------------

The primary outcome measure was late AMD, or each type of late AMD if the overall results for late AMD were not presented.

Study Selection
---------------

Searches were completed by 28 February 2007 and yielded 295 references. The abstracts of these articles were independently reviewed by two researchers (LP and CE) and relevant data (e.g., study design, risk factor, type of AMD) was recorded on a study-specific abstraction form. Full-text articles were then obtained based on the initial screening of abstracts and the data extraction form was completed. Any disagreements between the two reviewers in the abstract review or following selection of articles for full text review were resolved by discussion. The bibliographies of the full text articles that were reviewed were searched for relevant references.

In all, 128 unduplicated references were initially identified as being of potential relevance (the search was repeated in November 2008 and seven additional articles published in 2008 were included \[[@B27]-[@B32]\]), with 12 additional articles retrieved from the reference lists. From the total of 147 articles, 70 fulfilled all eligibility criteria and were selected for meta-analysis. One study was excluded since the outcome was determined by clinical criteria rather than retinal photography. In addition, 24 articles were excluded since authors reported progression for early AMD as well as late AMD. In the final pool, 45 articles were retained for the meta-analyses including articles with results from 18 prospective studies \[[@B24],[@B26],[@B33]-[@B49]\], and cross-sectional studies \[[@B12],[@B25],[@B28],[@B30],[@B31],[@B50]-[@B63]\], and 8 case control studies (Figure [1](#F1){ref-type="fig"}) \[[@B50],[@B64]-[@B70]\].

![**Study selection process**.](1471-2415-10-31-1){#F1}

Data Synthesis
--------------

We used Comprehensive Meta-Analysis software version 2 for all meta-analyses. An overall meta-analysis was performed for each risk factor if there were two or more risk estimates irrespective of study design. In addition, since the study design could influence the risk estimate, meta-analyses were performed for each major type of study within each risk factor. We conducted fixed-effects and random-effects meta-analyses to combine these outcomes across included studies by study design, estimating overall raw point estimates of each risk factor and their associated 95% confidence intervals (CI). The selection of fixed-effects vs. random-effects models was based on the reported I-squared value and associated p-value. If the p-value was \< 0.10 then random-effects was chosen, otherwise fixed-effects was selected, except when there was clear heterogeneity based on individual study results and in these instances the more conservative random-effects was selected. Forest plots were used to graphically present the significant findings. Funnel plots were produced to explore the potential for publication bias.

Results
=======

In total, data from 18 prospective, cross-sectional studies and 8 case control studies \[[@B12],[@B24]-[@B26],[@B28],[@B30],[@B31],[@B33]-[@B47],[@B49]-[@B54],[@B57]-[@B73]\] were included in the final analysis, contributing a sample of some 94,058 patients (ranging from 261 to 22,071) including 3,178 (ranging from 8 to 776) late AMD cases. Table [2](#T2){ref-type="table"} summarizes the characteristics of the 18 prospective and cross-sectional studies from which estimates were included in the meta-analysis. Funnel plots were reviewed and no evidence of publication bias was observed.

###### 

Summary of characteristics of the 18 prospective and cross sectional studies

  STUDY NAME                                                                 LOCATION      DATE OF STUDY          POPULATION   NUMBER OF LATE AMD SUBJECTS   AGE RANGE   \% MALE   METHOD OF FUNDUS CAPTURE   METHOD OF CLASSIFICATION
  -------------------------------------------------------------------------- ------------- ---------------------- ------------ ----------------------------- ----------- --------- -------------------------- ------------------------------------------------------------------
  AREDS \[[@B64]\]                                                           USA           1992-1998              4,519        776                           60-80       NA        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Baltimore Eye Study\*\[[@B91]\]                                            USA           1985-1988              4,396        48                            40+         NA        Retinal photo              International AMD
                                                                                                                                                                                                              
  Barbados Eye Study\*\[[@B42]\]                                             Barbados      1988-1992              2,374        12                            40-84       43        Retinal photo              Described in paper
                                                                                                                                                                                                              
  Beaver Dam Eye Study\[[@B24]-[@B26],[@B39],[@B47],[@B57],[@B92]\]          USA           1988-1990              4,926        72                            43-86       44        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Blue Mountains Eye Study\*\[[@B24]-[@B26],[@B35],[@B43],[@B46]\]           Australia     1992-1994              3,654        65                            49+         43        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Cardiovascular Health Study\[[@B40]\]                                      USA           1989-1990              5,201        35                            65+         60        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Copenhagen City Study\*\[[@B33],[@B49]\]                                   Denmark       1986-1988, 2000-2002   946          112                           60-80       49        Retinal photo              Described in paper
                                                                                                                                                                                                              
  European Study of Eye Disease (EUREYE)\[[@B12]\]                           Europe        2000-2003              4,752        158                           Aged 65+    45        Retinal photo              International AMD
                                                                                                                                                                                                              
  Funagata Study\[[@B30]\]                                                   Japan         2000-2002              3,676        8                             35+         51        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Los Angeles Latino Eye Study (LALES) \*\[[@B53],[@B54],[@B61]\]            USA           1997-2002              5,875        25                            40+         42        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Multi-ethnic Study of Atherosclerosis (MESA)\[[@B41],[@B59]\]              USA           2002-2004              6,176        27                            45-85       48        Retinal photo              WARMGS
                                                                                                                                                                                                              
  NHANES III\*\[[@B58]\]                                                     USA           1998-1994              8,270        54                            40+         47        Retinal photo              WARMGS
                                                                                                                                                                                                              
  PHS\[[@B34],[@B44]\]                                                       USA           1982-1989              22,071       64                            40+         100       Retinal photo              WARMGS
                                                                                                                                                                                                              
  Progression of Age-related Macular Degeneration Study (PARMDS)\[[@B45]\]   USA           1989-1998              261          NA                            60+         NA        Retinal photo              Modification of the Age-Related Eye Disease Study Grading system
                                                                                                                                                                                                              
  Pathologie Occulaires Liees a l\'age (POLA) \*\[[@B51],[@B52]\]            France        2002, 2006             2,183        41                            60+         43        Retinal photo              Fundus photo
                                                                                                                                                                                                              
  Proyecto VER\*\[[@B93]\]                                                   USA           1997-1999              2,780        15                            50+         39        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Rotterdam Study\*\[[@B25],[@B26],[@B36],[@B62],[@B94]\]                    Netherlands   1990-1993              6,251        104                           55+         40        Retinal photo              WARMGS
                                                                                                                                                                                                              
  Singapore Malay Eye Study (SiMES)\[[@B28],[@B31]\]                         Singapore     1992                   3,280        23                            40-80       52        Retinal photo              WARMGS

WARMGS: Wisconsin Age-Related Maculopathy Grading System; \* Studies included in the meta-analyses

\* From article referenced

Note: Case control studies were not included in this table

The findings for each risk factor except age are summarized in Table [3](#T3){ref-type="table"} and discussed separately in the following sections.

###### 

Summary Results from the Meta-analysis

  RISK FACTOR                 PROSPECTIVE   CROSS-SECTIONAL        CASE CONTROL                                   
  --------------------------- ------------- ---------------------- -------------- ----------------------- ------- -----------------------
                              **n**         **Overall estimate**   **n**          **Overall estimate**    **n**   **Overall estimate**
                                                                                                                  
  Gender (female)             2             1.01 (0.89 - 1.16)     2              1.06 (0.78 - 1.44)      2       1.00 (0.83 - 1.21)
                                                                                                                  
  Race (white vs. other)      3             0.91 (0.49 - 1.69)     3              1.09 (0.09 - 13.56)\*   1       4.2 (2.23 - 8.00)
                                                                                                                  
  Family History\*            0                                    1              3.95 (1.35 - 11.54)     2       6.18 (0.98 - 38.90)\*
                                                                                                                  
  Cataract surgery\*          4             3.05 (2.05 - 4.55)     2              1.59 (1.08 - 2.34)      3       1.54 (1.24 - 1.91)
                                                                                                                  
  Iris colour\*               5             0.98 (0.72 - 1.32)     4              0.88 (0.65 - 1.17)      2       0.60 (0.12 - 2.98)\*
                                                                                                                  
  Body Mass Index\*           9             1.28 (0.98 - 1.67)\*   10             1.21 (0.97 - 1.53)      2       1.52 (1.15 - 2.00)
                                                                                                                  
  Smoking\*                   5             1.86 (1.27 - 2.73)     7              3.58 (2.68 - 4.79)      6       1.78 (1.52 - 2.09)
                                                                                                                  
  Hypertension\*              4             1.02 (0.77 - 1.35)     6              1.15 (0.88 - 1.51)      3       1.48 (1.22 - 1.78)
                                                                                                                  
  Diabetes\*                  3             1.66 (1.05 - 2.63)     3              1.09 (0.61 - 1.92)      1       0.55 (0.06 - 4.87)
                                                                                                                  
  Cardiovascular Disease\*    7             1.22 (0.92 - 1.63)     9              1.12 (0.86 - 1.47)      6       2.20 (1.49 - 3.26)\*
                                                                                                                  
  Cerebrovascular Diseases    2             1.54 (0.82 - 2.90)     5              1.10 (0.69 - 1.75)      0       
                                                                                                                  
  Serum Cholesterol (Total)   4             0.99 (0.95 - 1.03)     5              0.94 (0.84 - 1.04)      1       4.66 (1.35 - 16.11)
                                                                                                                  
  Serum Cholesterol (HDL)     3             1.00 (0.97 - 1.02)     5              1.06 (0.80 - 1.39)      1       3.35 (0.92 - 12.23)
                                                                                                                  
  Serum Triglycerides         2             1.00 (0.77 - 1.30)     3              1.08 (0.89 - 1.30)      1       0.90 (0.25 - 3.24)
                                                                                                                  
  Plasma Fibrinogen\*         1             1.03 (0.81 - 1.32)     3              1.45 (1.22 - 1.73)      0       

n = number of estimates entered in the models; \*Figure is displayed

\* Estimates from random effects models. All other estimates are fixed effects.

Age
---

All studies found a strong association with increasing age (Table [4](#T4){ref-type="table"} and Figure [2](#F2){ref-type="fig"}) \[[@B31],[@B74]\].

###### 

Prevalence of late AMD by age (Adapted from Varma et al68 and Kawasaki et al29)

  Age       Los Angeles        Baltimore          Blue Mountains      Beaver Dam         Baltimore         Barbados          SiMES
  --------- ------------------ ------------------ ------------------- ------------------ ----------------- ----------------- -------
  40 - 49   0.0                0.0                                                       0.0               0.4 (0.0 - 0.8)   0
  50 - 59   0.2 (0.0 - 0.4)    0.5 (0.0 - 1.1)    0.0                 0.2 (0.0 - 0.4)    0.4 (0.0 - 0.8)   0.7 (0.2 - 1.2)   0.21
  60 - 69   0.3 (0.0 - 0.6)    0.7 (0.1 - 1.3)    0.5 (0.1 - 0.8)     0.8 (0.3 - 1.3)    0.4 (0.0 - 1.0)   0.4 (0.0 - 0.8)   0.39
  70 - 79   1.5 (0.5 - 2.5)    2.9 (1.5 - 4.4)    2.6 (1.6 - 3.6)     3.7 (2.5 - 4.9)    0.0               1.0 (0.0 - 2.0)   2.49
  ≥ 80      8.5 (3.5 - 13.5)   7.0 (2.0 - 12.0)   12.0 (8.7 - 15.4)   9.5 (6.2 - 12.8)   0.0               0.0               

![**Prevalence of late AMD by age (adapted from Varma et al**\[[@B61]\]**and Kawasaki et al**\[[@B19]\]).](1471-2415-10-31-2){#F2}

Gender
------

Two estimates from two case control studies \[[@B64],[@B65]\], two estimates from cross-sectional studies \[[@B25],[@B30]\], and two prospective studies \[[@B27],[@B75]\] contributed to this meta-analysis. Findings from this analysis suggest that there is no significant association between female gender and late AMD. In the case control studies, the overall OR for female gender was 1.00 (95% CI 0.83 - 1.21), in the cross-sectional studies, it was 1.06 (95% CI 0.78 - 1.44) (Figure [3](#F3){ref-type="fig"}). In the prospective studies, it was 1.01 (95% CI 0.89 - 1.16). Since the authors had not provided the confidence intervals, one study could not be included in the model \[[@B49]\].

![**Pooled odds ratio for late AMD by gender (female vs. male)**.](1471-2415-10-31-3){#F3}

Race/ethnicity
--------------

One case control study (AREDS) \[[@B64]\], two cross sectional studies (NHANES III and LALES) \[[@B53],[@B58]\] and two prospective studies (MESA, CHS) \[[@B41],[@B76]\] contributed to this analysis. All studies were based in the US population. In the MESA Study \[[@B41]\], there were no significant differences between whites (European origin), Asians (i.e. predominantly Chinese ancestry), Blacks (African Americans) or Hispanics in late AMD prevalence. In the NHANES III \[[@B58]\], there were no significant differences between Non-Hispanic White, Non-Hispanic Black (OR 0.34, 95%CI 0.10 - 1.18) and Mexican Americans (OR 0.25, 95% CI 0.07 - 0.90). In the LALES \[[@B53]\], individuals of Native American ancestry were nearly 15 times more likely to have geographic atrophy (95% CI 1.8 - 12.6) than Latinos. The OR was 0.91 (0.49 - 1.69) in prospective cohort studies and 1.09 (0.09 - 13.56) in cross-sectional studies for whites versus other races/ethnicities (Figure [4](#F4){ref-type="fig"}). An additional study, the Baltimore Eye Study \[[@B77]\], was identified; however, the use of differing nomenclatures in the Baltimore Eye Study to identify racial types (e.g., African American, Chinese, Mexican American) prevented its inclusion in the meta-analysis.

![**Pooled odds ratio for late AMD and by race/ethnicity (whites vs. other races/ethnicities)**.](1471-2415-10-31-4){#F4}

Family history
--------------

Two case control studies were included in the meta-analysis \[[@B68],[@B69]\]. Findings from the meta-analysis show an insignificant association between family history and late AMD (OR 6.18; 95% CI 1.94 - 6.61). This was supported by findings from a cross-sectional study (OR 3.95. 95% CI 1.35 - 11.54) (Figure [5](#F5){ref-type="fig"}) \[[@B60]\].

![**Pooled odds ratio for late AMD by family history (presence or absence)**.](1471-2415-10-31-5){#F5}

Cataract surgery
----------------

Estimates from three prospective cohort studies (i.e., Copenhagen, Blue Mountains, and Beaver Dam) \[[@B24],[@B27],[@B35],[@B38]\] at five-years and ten-years, and from five cross-sectional studies (Salisbury Eye Evaluation, Proyecto VER, Baltimore Eye Survey, and Blue Mountains) \[[@B63],[@B78]\], were analyzed. Only two case control studies \[[@B50],[@B66]\] were found. Analysis of the prospective cohort studies showed that previous cataract surgery is a strong risk factor for neovascular AMD (RR 3.05; CI 2.05 - 4.55). This finding is supported by the results of the meta-analysis of the cross-sectional studies (OR = 1.59; CI 1.08 - 2.34) (Figure [6](#F6){ref-type="fig"}).

![**Pooled odds ratio for late AMD by history of previous cataract surgery**.](1471-2415-10-31-6){#F6}

Smoking
-------

Estimates were reported from six prospective cohort studies \[[@B26],[@B33],[@B34],[@B42],[@B79]\], five case control studies \[[@B64],[@B65],[@B67],[@B68],[@B70]\] and five cross-sectional studies \[[@B12],[@B25],[@B28],[@B30],[@B51]\] contributed to the meta-analysis. Significant increases in AMD risk were seen in all the meta-analyses for current versus never smokers. The OR for case control studies was 1.78 (95% CI 1.52 - 2.09), and that from cross-sectional studies was 3.58 (95% CI 2.68 - 4.79). The RR obtained through analysis of prospective cohort studies was 1.86 (95% CI 1.27 - 2.73) (Figure [7](#F7){ref-type="fig"}).

![**Pooled odds ratio for late AMD by smoking status (current vs. never)**.](1471-2415-10-31-7){#F7}

Iris colour
-----------

Data from three prospective cohort studies \[[@B26],[@B27],[@B47]\], from two control studies \[[@B65],[@B68]\] and a pooled estimate from a cross sectional study \[[@B25]\] were used in the meta-analysis. Two studies were not used because the authors had not provided the confidence interval of the estimate \[[@B37],[@B64]\], or because the data had already been considered within a pooled analysis \[[@B58]\]. The meta-analysis of the prospective cohort and cross-sectional studies suggests that darker iris pigmentation (brown vs. blue eyes) is protective, but the overall results were not significant (OR 0.88; 95% CI 0.65 - 1.17 cross-sectional studies and RR 0.98; 95% CI: 0.72 - 1.32 for prospective studies). The case control results support this finding (0.60; 95% CI 0.12 - 2.98) (Figure [8](#F8){ref-type="fig"}).

![**Pooled odds ratio for late AMD by iris color (brown vs. blue eyes)**.](1471-2415-10-31-8){#F8}

Body Mass Index (BMI)
---------------------

Seven prospective cohort studies (Copenhagen, CHS, PHS, PARMDS, Beaver Dam, Rotterdam, Blue Mountains) \[[@B26],[@B33],[@B44]-[@B46],[@B80]\] and six cross-sectional studies (POLA, Beaver Dam, Rotterdam, Blue Mountains, LALES, SiMES) \[[@B25],[@B28],[@B52],[@B54]\] contributed to the meta-analysis. Analysis of the prospective studies showed an adverse effect of being overweight/obese and the risk of late AMD (RR 1.28; 95% CI 0.98 - 1.67). Cross-sectional study findings were in the same direction but did not reach statistical significance (OR 1.21; 95% CI 0.97 - 1.53). However, the two case control studies \[[@B64],[@B67]\] did achieve statistical significance (OR 1.52; 95% 1.15 - 2.00) (Figure [9](#F9){ref-type="fig"}).

![**Pooled odds ratio for late AMD by body mass index (obese vs. non-obese)**.](1471-2415-10-31-9){#F9}

Hypertension
------------

Estimates from five prospective cohort studies \[[@B26],[@B27],[@B42],[@B46]\], three cases control studies \[[@B64],[@B65],[@B67]\], and from seven cross-sectional studies \[[@B25],[@B28],[@B30],[@B52],[@B54]\] contributed to this analysis. None of the analyses showed statistically significant associations (prospective cohort RR 1.02; 95% CI 0.77 - 1.35; cross-sectional studies OR 1.15; 95% CI: 0.88 - 1.51). The three case control studies did identify a significant association between presence of hypertension and late AMD (OR 1.48; 95% CI 1.22 - 1.78) (Figure [10](#F10){ref-type="fig"}).

![**Pooled odds ratio for late AMD by hypertension (presence or absence)**.](1471-2415-10-31-10){#F10}

Diabetes
--------

Estimates from four prospective cohort studies \[[@B24],[@B42],[@B46]\] and two cross-sectional estimates \[[@B52],[@B54],[@B60]\] contributed to the meta-analysis. Based on the data from the prospective cohort studies, the presence of diabetes was associated with an increased risk of late AMD (RR 1.66; 95% CI 1.05 - 2.63). In the cross-sectional estimates that used data from two studies, associations were nonsignificant (OR 1.09; 95% CI 0.61 - 1.92). Only one case control study \[[@B65]\] showed nonsignificant association with diabetes (OR 0.55; 95% CI 0.06 - 4.87) (Figure [11](#F11){ref-type="fig"}).

![**Pooled odds ratio for late AMD by diabetes (presence or absence)**.](1471-2415-10-31-11){#F11}

History of Cardiovascular Disease
---------------------------------

Five prospective cohort studies (including pooled estimates) \[[@B26],[@B33],[@B42],[@B46]\] four case control studies \[[@B65]-[@B68]\] and seven cross-sectional studies \[[@B28],[@B52],[@B54],[@B58]\] (including pooled estimates \[[@B25]\]) contributed to the meta-analysis of history of cardiovascular disease (self or medical report) and late AMD. As previously mentioned, some estimates \[[@B49],[@B81]\] were not retained in the analysis. No significant association was found in the prospective cohort and the cross-sectional studies (RR 1.22, 95% CI 0.92 - 1.63 and OR 1.12; 95% CI 0.86 - 1.47). A significant association was observed in the case control studies, with around double the odds of late AMD in individuals with cardiovascular disease (OR 2.20; 95% CI 1.48 - 3.26) (Figure [12](#F12){ref-type="fig"}).

![**Pooled odds ratio for late AMD by cardiovascular disease (presence or absence)**.](1471-2415-10-31-12){#F12}

History of Cerebrovascular Diseases
-----------------------------------

Three prospective cohort studies \[[@B26],[@B46]\] and six cross-sectional studies \[[@B25],[@B28],[@B52],[@B54]\] were included in the meta-analysis of history of cerebrovascular diseases and late AMD (Figure [13](#F13){ref-type="fig"}). No significant associations were found (RR 1.54; 95% CI 0.82 - 2.90 and OR 1.10, 95%CI 0.69 - 1.75 for the prospective and the cross-sectional studies, respectively).

![**Pooled odds ratio for late AMD by cerebrovascular disease (presence or absence)**.](1471-2415-10-31-13){#F13}

Biological markers
------------------

Five prospective cohort studies \[[@B26],[@B33],[@B40],[@B46]\] (including one pooled estimate), and six cross-sectional studies \[[@B28],[@B30],[@B52]\] (including one pooled estimate \[[@B25]\]), one case control \[[@B67]\] of serum total cholesterol and of serum high-density lipoprotein cholesterol contributed to the meta-analysis (data not shown). Three studies \[[@B49],[@B57],[@B82]\] were not included in the meta-analysis. The pooled odds ratios and relative risks were non-significant for both serum cholesterol measures.

Neither the two prospective cohort studies \[[@B27],[@B46]\] (RR 1.0; 95% CI 0.77 - 1.30) nor the cross-sectional studies\[[@B28],[@B52],[@B60]\] (OR 1.08; 95% CI 0.89 - 1.30), found an association between serum triglycerides and late AMD (data not shown).

A significant increase in risk of late AMD with increased plasma fibrinogen was observed in two cross-sectional studies \[[@B58]-[@B60]\], (OR 1.45; 95% CI 1.22 - 1.73). There was only one estimate from a prospective study \[[@B46]\] and it did not support this finding (OR 1.03; 95% CI 0.81 - 1.32) of significance in the cross-sectional studies (Figure [14](#F14){ref-type="fig"}).

![**Pooled odds ratio for late AMD by plasma fibrinogen**.](1471-2415-10-31-14){#F14}

None of the studies which measured C-reactive protein \[[@B36]\] were eligible for inclusion in our meta-analysis.

Discussion
==========

Identifying patients at high risk of late AMD, particularly neovascular AMD, is important from both public health and clinical perspectives as this would facilitate detection of disease before the onset of irreversible visual loss enabling earlier intervention. Of the 16 risk factors identified in our systematic review and meta-analysis, age, current smoking, cataract surgery, and potentially family history were strongly and consistently associated with late AMD. All of these are easily assessed through discussions with patients and do not entail a lengthy medical history taking or laboratory evaluations. Other significant factors with a lower strength of association (risk estimates generally 1.5 or less) were BMI, hypertension, a history of cardiovascular disease and plasma fibrinogen. All of these factors are associated with cardiovascular disease and are also likely to be measured and monitored in the primary care setting.

Our meta-analysis confirmed the increased risks of late AMD associated with advancing age (especially for the oldest age groups of 80 years and over), current cigarette smoking, and previous cataract surgery. The relationship of cataract surgery and late AMD was previously reported in a pooled analysis of 3 studies in different continents \[[@B26]\]. Although this association could reflect shared risk factors and the fact that both are diseases that affect the ageing eye, there is concern that surgery may predispose the operated eye to the development of neovascular AMD. We further confirmed the association with family history of AMD, consistent with the growing recognition of major genes involved in AMD (e.g., complement factor H and C3, LOCS 3877, HTRA 1) \[[@B21],[@B83]-[@B86]\].

Vascular diseases, including myocardial infarction, stroke, angina, and hypertension are thought to be pathogenic factors for the development of late AMD. Our meta-analysis showed that while the magnitude of the ORs were inconsistent across studies, the pooled estimates for case-control studies were statistically significant for both cardiovascular disease (OR 2.20; 95% CI 1.49 - 3.26) and hypertension (OR 1.48, 95% CI 1.22 - 1.78). The association of diabetes and late AMD is also less consistent, and while prospective studies showed a significant association, this was not significant in the cross-sectional or case-control studies. The relationship between higher BMI and late AMD could be explained by shared risk factors (e.g., hypertension), or potential unmeasured confounders (e.g., nutritional factors). Our analysis also indicated that, based only on US data, people of European origin were at increased risk compared to other ethnic groups but at present the evidence for risks associated with other specific ethnic groups is inadequate. These are areas of future research.

Our study has several limitations. Although we selected only studies that reported some adjustment for confounding factors, we could not ascertain the appropriateness or completeness of adjustment in the studies. Second, the data included in some studies may have been too crude and also subject to measurement error. For example, a \'history of cardiovascular disease\' may encompass a spectrum of conditions, from asymptomatic angina to myocardial infarction; this was not often specified. Such potential measurement errors would likely dilute effects in the meta-analysis. Third, we did not consider ocular factors (e.g., presence of large drusen), that have been found to be strong predictors of progression to late AMD, as we felt they could not be easily ascertained by family physicians. Neither did we consider dietary factors, such as the consumption of vegetables rich in carotenoids (lutein and zeaxanthin) or zinc and antioxidant vitamin supplementation, fish or omega-3 fatty acids in the diet, or glycemic index, because the methods for estimating such risk factors in the setting of primary health care is difficult without access to specialised personnel and resources \[[@B6],[@B87]-[@B89]\]. Fourth, despite strong associations of AMD with genetic factors, we felt that genetic testing was not readily available in general clinical practice. Fifth, we included only English language articles because a preliminary assessment did not identify any non-English language articles that fitted our inclusion criteria. Nonetheless, many studies included in this review were from non-white populations (e.g., Chinese, Malay Asians) and thus, we believe our results can be generalisable to different populations in different countries around the world. Sixth, we only included articles that were identified in the Medline and Cochrane databases. Expanding the search to EMBASE may have identified additional articles; however, given the extensive hand searching of bibliographies and the experience of the authors we feel it is unlikely any relevant articles were missed. Seventh, the assessment of the quality of the publications was performed as part of this study to provide supplementary evidence of the internal and external validity of the data. However, ultimately, we decided to present the data based on the type of study design reported in the publication: cohort, cross sectional and case control. Large, epidemiological, cohort studies had the advantage over other study designs in that they removed any temporal or causal ambiguity as the exposure precedes the disease and if follow-up is not biased selection bias is less of a problem than in other study designs \[[@B90]\]. Finally, whether the study findings could be used as prognostic information to refer patients with higher risk of AMD requires further research. The observed odds ratios were generally small, and there are limited interventions to prevent AMD.

Conclusions
===========

Our systematic review and meta-analysis identified four strong and consistent risk factors for late AMD (increasing age, current smoking, previous cataract surgery and an AMD family history) and a further four risk factors showing significant and moderate strength of associations (high BMI, history of cardiovascular disease, hypertension and plasma fibrinogen). This study provides additional information for primary care physicians, general ophthalmologists and other eye care professionals to counsel their patients on AMD risk.
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